Prescribing Information Important Safety Information

References

  1. ADA National Network. Glossary of ADA terms. Accessed September 29, 2018. https://adata.org/glossary-terms#D
  2. Alfalah M, Keiser M, Leeb T, et al. Compound heterozygous mutations affect protein folding and function in patients with congenital sucrase-isomaltase deficiency. Gastroenterology. 2009;136(3):883-92. doi:10.1053/j.gastro.2008.11.038
  3. Bell RR, Draper HH, Bergan JG. Sucrose, lactose, and glucose tolerance in northern Alaskan Eskimos. Am J Clin Nutr. 1978;26(11):1185-90. doi: 10.1093/ajcn/26.11.1185
  4. Bhagavan NV. Metabolic homeostasis. In: Bhagavan NV, ed. Medical Biochemistry, Fourth Edition. New York, NY; Harcourt/Academic Press: 2002.
  5. Danialifar TF, Chumpitazi BP, Mehta DI, Di Lorenzo C. Genetic and acquired sucrase-isomaltase deficiency: A clinical review. J Pediatr Gastroenterol Nutr. 2024;78(4):774-82. doi:10.1002/jpn3.12151
  6. Ellestad-Sayed JJ, Haworth JC, Hildes JA. Disaccharide malabsorption and dietary patterns in two Canadian Eskimo communities. Am J Clin Nutr. 1978;31(8):1473-8. doi: 10.1093/ajcn/31.8.1473
  7. Gericke B, Amir M, Naim HY. The multiple roles of sucrase-isomaltase in the intestinal physiology. Mol Cell Pediatr. 2016;3(1):2-6. doi:10.1186/s40348-016-0033-y
  8. Gudmand-Høyer E, Krasilnikoff PA, Skovbjerg H. Sucrose-isomaltose malabsorption. Adv Nutr Res. 1984;6:233-69. doi:10.1007/978-1-4613-2801-8_9
  9. Hackenmuller SA, Grenache DG. Reference intervals for intestinal disaccharidase activities determined from a non-reference population. J Appl Lab Med. 2016;1(2):172-80. doi:10.1373/jalm.2016.020388
  10. Hamaker BR, Lee BH, Quezada-Calvillo R. Starch digestion and patients with congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 2012;55(suppl 2):S24-8. doi:10.1097/01.mpg.0000421404.42386.2d
  11. Jacob R, Zimmer KP, Schmitz J, et al. Congenital sucrase-isomaltase deficiency arising from cleavage and secretion of a mutant form of the enzyme. J Clin Invest. 2000;106(2):281-7. doi: 10.1172/JCI9677
  12. Keiser M, Alfalah M, Pröpsting MJ, et al. Altered folding, turnover, and polarized sorting act in concert to define a novel pathomechanism of congenital sucrase-isomaltase deficiency. J Biol Chem. 2006;281(20):14393-9. doi: 10.1074/jbc.M513631200
  13. Naim HY, Heine M, Zimmer KP. Congenital sucrase-isomaltase deficiency: heterogeneity of inheritance, trafficking, and function of an intestinal enzyme complex. J Pediatr Gastroenterol. 2012;55(suppl 2):S13-20. doi:10.1097/01.mpg.0000421402.57633.4b
  14. National Organization for Rare Disorders. Congenital sucrase-isomaltase deficiency. Last updated February 7, 2018. https://rarediseases.org/rare-diseases/disaccharide-intolerance-i/
  15. Nichols BL Jr, Adams B, Roach CM, Ma CX, Baker SS. Frequency of sucrase deficiency in mucosal biopsies. J Pediatr Gastroenterol Nutr. 2012;55(suppl 2):S28-30. doi: 10.1097/01.mpg.0000421405.42386.64
  16. Peterson ML, Herber R. Intestinal sucrase deficiency. Trans Assoc Am Physicians. 1967;80:275-83.
  17. Quezada-Calvillo R, Robayo-Torres CC, Ao Z, et al. Luminal substrate “brake” on mucosal maltase-glucoamylase activity regulates total rate of starch digestion to glucose. J Pediatr Gastroenterol Nutr. 2007;45(1):32-43. doi:10.1097/MPG.0b013e31804216fc
  18. Ritz V, Alfalah M, Zimmer KP, et al. Congenital sucrase-isomaltase deficiency because of an accumulation of the mutant enzyme in the endoplasmic reticulum. Gastroenterology. 2003;125(6):1678-85. doi:10.1053/j.gastro.2003.09.022
  19. Sander P, Alfalah M, Keiser M, et al. Novel mutations in the human sucrase-isomaltase gene (SI) that cause congenital carbohydrate malabsorption. Human Mutat. 2006;27(1):119. doi:10.1002/humu.9392
  20. Smith H, Romero B, Flood E, Boney A. The patient journey to diagnosis and treatment of congenital sucrase-isomaltase deficiency. Qual Life Res. 2021;30(8):2329-38. doi:10.1007/s11136-021-02819-z
  21. Social Security Administration. Benefits planner: disability, how you qualify. Accessed September 29, 2018. http://www.ssa.gov/planners/disability/qualify.html
  22. Social Security Administration. Disability benefits: how you qualify. Accessed June 4, 2023. https://www.ssa.gov/benefits/disability/qualify.html
  23. Treem WR. Clinical aspects and treatment of congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 2012;55(suppl 2):S7-13. doi:10.1097/01.mpg.0000421401.57633.90
  24. Treem WR. Congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1995;21(1):1-14. doi:10.1097/00005176-199507000-00001
  25. Uhrich S, Wu Z, Huang J, Scott CR. Four mutations in the SI gene are responsible for the majority of clinical symptoms of CSID. J Pediatr Gastroenterol Nutr. 2012; 55(2):S34-5. doi:10.1097/01.mpg.0000421408.65257.b5
  26. U.S. Equal Employment Opportunity Commission. Policy guidance on executive order 13164: establishing procedures to facilitate the provision of reasonable accommodation. Last updated October 20, 2000. http://www.eeoc.gov/policy/docs/accommodation_procedures.html
  27. Welsh JD, Poley JR, Bhatia M, Stevenson DE. Intestinal disaccharidase activities in relation to age, race, and mucosal damage. Gastroenterology. 1978;75(5):847-55.

Take Back Control of Your Life

©2025, All Rights Reserved. Presented by QOL Medical, LLC. Do Not Sell/Share My Personal Information
SucraidASSIST.com
View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Collapse Important Safety Information
Expand Important Safety Information

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Tell your doctor if you are allergic to, have ever had a reaction to, or have ever had difficulty taking yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. If you notice any swelling or have difficulty breathing, get emergency help right away.
  • Sucraid® does not break down some sugars that come from the digestion of starch. You may need to restrict the amount of starch in your diet. Your doctor will tell you if you should restrict starch in your diet.
  • Tell your doctor if you have diabetes, as your blood glucose levels may change if you begin taking Sucraid®. Your doctor will tell you if your diet or diabetes medicines need to be changed.
  • Some patients treated with Sucraid® may have worse abdominal pain, vomiting, nausea, or diarrhea. Constipation, difficulty sleeping, headache, nervousness, and dehydration have also occurred in patients treated with Sucraid®. Check with your doctor if you notice these or other side effects.
  • Sucraid® has not been tested to see if it works in patients with secondary (acquired) sucrase deficiency.
  • NEVER HEAT SUCRAID® OR PUT IT IN WARM OR HOT BEVERAGES OR INFANT FORMULA. Do not mix Sucraid® with fruit juice or take it with fruit juice. Take Sucraid® as prescribed by your doctor. Normally, half of the dose of Sucraid® is taken just before a meal or snack and the other half is taken during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.